로딩 중…
지수 로딩 중…
Royalty Pharma plc
RPRX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$58.93+0.79%
2026-09-17
Financials
Valuation Metrics
Royalty Pharma plc's Market Cap is $33.93B. At end of 2025 it was $16.69B. Ranked #423 of 3,121 in US market (top 14%), #123 of 1,463 on NASDAQ (top 8%), #23 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.93B | US#423/3,121 Sec#23/266 |
| Revenue | $2.54B | US#1,300/3,121 Sec#36/266 |
| Net Income | $815M | US#632/3,121 Sec#23/266 |
| Total Assets | $19.82B | US#622/3,121 Sec#23/266 |
| Net Assets | $6.83B | US#569/3,121 Sec#21/266 |
| Employees | 100 | US#2,631/3,121 Sec#180/266 |
| Value | ||
| P/E | 41.62x | US#1,829/3,121 Sec#51/266 |
| P/B | 4.97x | US#2,220/3,121 Sec#141/266 |
| P/S | 13.38x | US#2,762/3,121 Sec#122/266 |
| EV/EBITDA | 24.53x | US#2,094/3,121 Sec#57/266 |
| FCF Yield | 8.77% | US#747/3,121 Sec#25/266 |
| Profitability | ||
| ROE | 11.93% | US#1,164/3,121 Sec#45/266 |
| ROA | 4.11% | US#1,209/3,121 Sec#55/266 |
| Op. Margin | 62.34% | US#54/3,121 Sec#2/266 |
| Revenue Growth | 10.01% | US#1,268/3,121 Sec#100/266 |
| Earnings Growth | -20.13% | US#1,555/3,121 Sec#41/266 |
| Financial Health | ||
| Debt Ratio | 146.85% | US#1,482/3,121 Sec#188/266 |
| Total Debt | $8.96B | US#452/3,121 Sec#21/266 |
| FCF | $2.98B | US#273/3,121 Sec#17/266 |
| Cash | $812M | US#787/3,121 Sec#37/266 |
| Current Ratio | 1.29x | US#1,899/3,121 Sec#249/266 |
| Net Debt/EBITDA | 4.75x | US#1,974/3,121 Sec#71/266 |
| Dividend | ||
| Div. Yield | 1.18% | US#1,242/3,121 Sec#21/266 |
| Div. Growth | 0.47% | US#1,195/3,121 Sec#21/266 |
| Performance | ||
| 1Y Return | 65.35% | US#393/3,121 Sec#88/266 |
| 1M Return | -1.27% | US#1,116/3,121 Sec#106/266 |
| From 52W High | -8.47% | US#589/3,121 Sec#42/266 |
| 1Y MDD | -8.58% | US#13/3,121 Sec#1/266 |
| Trading | ||
| Volume | 1,873,774 shares | US#873/3,121 Sec#89/266 |
| Trading Value | $110M | US#753/3,121 Sec#46/266 |
| Per Share | ||
| EPS | $1.42 | US#1,543/3,121 Sec#41/266 |
| BPS | $11.87 | US#1,722/3,121 Sec#62/266 |
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.